Employees of the Russian Direct Investment Fund have agreed with the Chinese company Shenzhen Yuanxing Gene-tech to produce Sputnik V vaccine in China. It is expected to produce 60 million doses.
"The volume produced will deliver vaccines to 30 million people. Commercial production of the vaccines is scheduled to start in May 2021," RDIF said on its official website.
The Sputnik V vaccine has already been registered in 57 countries with a population of 1.5 billion people. The effectiveness of the drug reaches 91.6%.
"Sputnik V is one of the best vaccines in the world. The partnership with Shenzhen Yuanxing Gene-tech will expand capacity to increase production of the drug, which continues to grow in demand around the world," said Kirill Dmitriev, head of RDIF.
Last week, RDIF announced Serbia's desire to launch production of Sputnik V. The start of production together with the Institute of Virology, Vaccines and Sera Torlac is scheduled for May 2021.
Photo: from open sources